MAPT and Alzheimer disease: It is unknown whether the H3K9me2/EHMT2 levels in PFC increase in an age‐dependent manner in AD humans and Tau AD models, and whether elevation of H3K9me2/EHMT2 is an upstream event prior to NFT formation/synaptic dysfunction/behavioral deficits.